A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis

Expert Review of Clinical Immunology

Volumn 12, Issue 5, 2016, Pages 595-602

  Shabaninejad, Hosein ^a   Asgharzadeh, Asra ^a   Rezaei, Nima ^b   Rezapoor, Aziz ^c  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

efficacy; Intravenous immunoglobulin; primary immunodeficiency; safety; Subcutaneous immunoglobulin

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ARTICLE; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INTERMETHOD COMPARISON; MEDLINE; META ANALYSIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SCOPUS; SYSTEMATIC REVIEW; ADULT; BLOOD; COMPARATIVE STUDY; IMMUNOLOGIC DEFICIENCY SYNDROMES; STANDARDS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS;

EID: 84961215659     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2016.1155452     Document Type: Article

References (49)

1. Borte S, Wang N, Oskarsdóttir S, et al. Newborn screening for primary immunodeficiencies: beyond SCID and XLA. Ann N Y Acad Sci. 2011; 1246: 118-130.
2. Borte S, vonDöbeln U, Hammarström L. Guidelines for newborn screening of primary immunodeficiency diseases. Curr Opin Hematol. 2013; 20: 48-54.
3. Aghamohammadi A, Moin M, Rezaei N. History of primary immunodeficiency diseases in Iran. Iran J Pediatr. 2010; 20: 16.
4. Rezaei N, Aghamohammadi A, Notarangelo LD, editors. Primary immunodeficiency diseases: definition, diagnosis, and management. Berlin: Springer Science & Business Media; 2008 Aug 6.
5. Rezaei N, Abolhassani H, Aghamohammadi A, et al. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011; 7: 301-306.
6. Peter JG, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy. 2014; 6: 853-869.
7. Gardulf A, Nicolay U, Asensio O, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004; 114 (4): 936-942.
8. Liu Z, Albon E, Hyde C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. Birmingham: University of Birmingham, Department of Public Health and Epidemiology; 2005.
9. Wasserman RL. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency. Expert Rev Clin Immunol. 2014; 10: 325-337.
10. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008; 28: 413-437.
11. Hammarstrom L, Gardulf A, Edvard Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991; 338: 162-166.
12. Hansen S, Gustafson R, Smith C, et al. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol. 2002; 104: 237-241.
13. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007; 21: 105-116.
14. Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995; 345: 365-369.
15. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000; 20: 94-100.
16. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007; 96: 1474-1478.
17. Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015; 179: 146-160.
18. Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012; 32: 1180-1192.
19. Bezrodnik L, Gómez Raccio A, Belardinelli G, et al. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina. J Clin Immunol. 2013; 33: 1216-1222.
20. Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol. 2013; 173: 365-371.
21. Kanegane H, Imai K, Yamada M, et al. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol. 2014; 34: 204-211.
22. Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol. 2014; 34: 1015-1017.
23. Vultaggio A, Azzari C, Milito C, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig. 2015; 35: 179-185.
24. Empson MB, Tang MLK, Pearce LKC, et al. Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, evogam®, in primary immunodeficiency. J Clin Immunol. 2012; 32: 897-906.
25. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immuno. 2011; 31: 323-331.
26. Jolles S, Bernatowska E, De Gracia J, et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. J Clin Immunol. 2011; 141: 90-102.
27. Borte M, Quinti I, Soresina A, et al. Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol. 2011; 31: 952-961.
28. Wasserman RL, Melamed I, Nelson Jr. RP, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011; 50: 405-414.
29. Wasserman RL1, Irani AM, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010; 161: 518-526.
30. Hoffmann F, Grimbacher B, Thiel J, et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010; 15: 238.
31. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immuno. 2010; 30: 301-307.
32. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immuno. 2010; 30: 734-745.
33. Quinti I, Soresina A, Agostini C, et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol. 2008; 28: 263-267.
34. Gelfand EW, Hanna K. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients. J Clin Immunol. 2006; 26: 284-290.
35. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006; 26: 265-273.
36. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol. 2006; 26: 177-185.
37. Eijkhout H, Van Den Broek P, Van Der Meer J. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med. 2003; 61: 213-217.
38. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998; 79: 48-51.
39. Schiff RI, Williams LW, Nelson RP, et al. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol. 1997; 17: 21-28.
40. McCormack PL. Immune globulin subcutaneous (Human) 20%: in primary immunodeficiency disorders. Drugs. 2012; 72: 1087-1097.
41. Lemieux R, Bazin R, Néron S. Therapeutic intravenous immunoglobulins. Mol Immunol. 2005; 42: 839-848.
42. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004; 112: 1-7.
43. Högy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005; 6: 24-29.
44. Haddad L, Perrinet M, Parent D, et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution. La Revue De Medecine Interne/Fondee. Par La Societe Nationale Francaise De Medecine Interne, Rev Med Interne. 2006; 27: 924-926.
45. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immuno. 2006; 26: 65-72.
46. Membe SK, Ho C, Cimon K, et al. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol Allergy Clin North Am. 2008; 28: 861-874.
47. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010; 6: 1.
48. Borte M, Pac M, Serban M, et al. Efficacy and safety of Hizentra ®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol. 2011; 31: 752-761.
49. Ho C, Membe S, Cimon K. An overview of subcutaneous vs. intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic analysis. CADTH. HTA. 2008; 36: 1-8.